Abstract
Our understanding of the genetic and non-genetic molecular alterations associated with colorectal cancer (CRC) progression and therapy resistance has markedly expanded in the recent years. In addition to their effects on tumor biology, targeted therapies can have effects on host immune responses. However, the mechanisms by which immune cells organize tumor microenvironments to regulate T-cell activity need to be comprehensively defined. There is good evidence in the literature that alterations in different members of the MAPK superfamily (mainly ERKs and p38 MAPKs) modify the inflammatory response and antitumor immunity, enhancing metastatic features of the tumors. In addition, a plethora of alterations that emerge at relapse often converge on the activation of MAPKs, particularly, ERKs, which act in concert with other oncogenic signals to modulate cellular homeostasis and clonal evolution during targeted therapies. Herein, we discuss how this knowledge can be translated into drug development strategies aimed at increasing tumor antigenicity and antitumor immune responses. Insights from these studies could provide a framework for considering additional combinations of targeted therapies and immunotherapies for the treatment of CRC.
Keywords: MAPKs, colorectal cancer, immune resistance, immune check point inhibitors, immunotherapy, ERKs, p38 MAPKs.
Current Medicinal Chemistry
Title:Emerging Insight into MAPK Inhibitors and Immunotherapy in Colorectal Cancer
Volume: 24 Issue: 14
Author(s): Massimo Pancione*, Guido Giordano, Pietro Parcesepe, Luigi Cerulo, Luigi Coppola, Anais Del Curatolo, Fabiana Conciatori, Michele Milella and Almudena Porras
Affiliation:
- Department of Sciences and Technologies, University of Sannio, Via Port'Arsa, 1182100 Benevento,Italy
Keywords: MAPKs, colorectal cancer, immune resistance, immune check point inhibitors, immunotherapy, ERKs, p38 MAPKs.
Abstract: Our understanding of the genetic and non-genetic molecular alterations associated with colorectal cancer (CRC) progression and therapy resistance has markedly expanded in the recent years. In addition to their effects on tumor biology, targeted therapies can have effects on host immune responses. However, the mechanisms by which immune cells organize tumor microenvironments to regulate T-cell activity need to be comprehensively defined. There is good evidence in the literature that alterations in different members of the MAPK superfamily (mainly ERKs and p38 MAPKs) modify the inflammatory response and antitumor immunity, enhancing metastatic features of the tumors. In addition, a plethora of alterations that emerge at relapse often converge on the activation of MAPKs, particularly, ERKs, which act in concert with other oncogenic signals to modulate cellular homeostasis and clonal evolution during targeted therapies. Herein, we discuss how this knowledge can be translated into drug development strategies aimed at increasing tumor antigenicity and antitumor immune responses. Insights from these studies could provide a framework for considering additional combinations of targeted therapies and immunotherapies for the treatment of CRC.
Export Options
About this article
Cite this article as:
Pancione Massimo*, Giordano Guido, Parcesepe Pietro, Cerulo Luigi, Coppola Luigi, Curatolo Del Anais, Conciatori Fabiana, Milella Michele and Porras Almudena, Emerging Insight into MAPK Inhibitors and Immunotherapy in Colorectal Cancer, Current Medicinal Chemistry 2017; 24(14) . https://dx.doi.org/10.2174/0929867324666170227114356
DOI https://dx.doi.org/10.2174/0929867324666170227114356 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
DNA Methylation: An Epigenetic Insight into Type 2 Diabetes Mellitus
Current Pharmaceutical Design Structure and Mechanism of Arylamine N-Acetyltransferases
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Adrenergic Receptors as Novel Targets for Cancer Therapy (Guest Editors: D.G. Powe and F. Entschladen)]
Current Cancer Therapy Reviews L-Arginine Modulates Glucose and Lipid Metabolism in Obesity and Diabetes
Current Protein & Peptide Science FoxO Proteins: Regulation and Molecular Targets in Liver Cancer
Current Medicinal Chemistry Autumn Royal and Egnatia Grape Extracts Differently Modulate Cell Proliferation in Human Colorectal Cancer Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets The Relationship Between Oncogene Expression and Clinical Outcome in Endometrial Carcinoma
Current Cancer Drug Targets Wnt Signaling in Development, Disease and Translational Medicine
Current Drug Targets Histone Deacetylase Inhibitors in Cancer Therapy: New Compounds and Clinical Update of Benzamide-Type Agents
Current Topics in Medicinal Chemistry Applications of Venom Proteins as Potential Anticancer Agents
Protein & Peptide Letters Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent
Current Drug Safety Anticancer Agents Derived from Natural Products
Mini-Reviews in Medicinal Chemistry Cancer-Type Organic Anion Transporting Polypeptide 1B3: Current Knowledge of the Gene Structure, Expression Profile, Functional Implications and Future Perspectives
Current Drug Metabolism ABC Transporters as Potential Targets for Modulation of Drug Resistance
Mini-Reviews in Medicinal Chemistry Radiation Dosimetry Aspects of <sup>177</sup>Lu
Current Radiopharmaceuticals Drug Discovery and Design for Complex Diseases through QSAR Computational Methods
Current Pharmaceutical Design Editorial (Thematic Issue: Ceramics, Nanotubes, Advanced Materials: Theoretical and Experimental Structure-Property Relationships - Part II)
Current Physical Chemistry The Significance of Transferrin Receptors in Oncology: the Development of Functional Nano-based Drug Delivery Systems
Current Drug Delivery Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology The Implication of Platelet Activating Factor in Cancer Growth and Metastasis: Potent Beneficial Role of PAF-Inhibitors and Antioxidants
Infectious Disorders - Drug Targets